The Flow Cytometry Core provides USC Norris Comprehensive Cancer Center (NCCC) members access to advanced multi-parameter cellular analytic and cell sorting capabilities which includes the fluorescence activated cell sorting (FACS) of various populations of cells to provide a purified cell population for the researchers. The Core also provides expertise to allow investigators to analyze the expression of various markers on a cell population using fluorescence-based methods. This Core is administratively managed by the Broad Center for Regenerative Medicine and Stem Cell Research (CSCRM). Previously, flow cytometry services were provided by a core facility managed by NCCC with partial support from the CCSG. On December 1, 2009, NCCC partnered with CSCRM, who took over the provision of flow cytometry services to NCCC investigators under the directorship of Dr. Gregor Adams. This transition was a direct result of the NCCC Executive Committee's review of its shared resources in mid-2008, and endorsed by the NCCC's External Advisory Committee in April 2009. The partnership benefits NCCC investigators by giving them access to newer cytometers with more capabilities, as well as a reduction in the cost of flow cytometry services. The Core currently maintains four cytometers, a Beekman Coulter CyAn analyzer, a BD LSR II analyzer, BD FACSAria and BD FACSAria 11 cell sorters. The LSRII and the Aria are equipped with a 350 nm UV, a 488 nm argon laser, and a 635 nm red diode laser, while the Aria II is equipped with a 405 nm violet laser, a 488 nm argon laser and a 633 nm red diode laser, which will ultimately permit up to 15 parameter analysis.

Public Health Relevance

Many cancer research projects require the isolation of a purified population of cells for analysis. The Flow Cytometry Core provides all of the necessary expertise and facilities to perform these experiments. This is an essential component of research aimed at treating many malignant conditions.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Southern California
Los Angeles
United States
Zip Code
Lawrenson, Kate; Grun, Barbara; Lee, Nathan et al. (2015) NPPB is a novel candidate biomarker expressed by cancer-associated fibroblasts in epithelial ovarian cancer. Int J Cancer 136:1390-401
Milam, Joel E; Meeske, Kathleen; Slaughter, Rhona I et al. (2015) Cancer-related follow-up care among Hispanic and non-Hispanic childhood cancer survivors: The Project Forward study. Cancer 121:605-13
Maus, M K H; Hanna, D L; Stephens, C L et al. (2015) Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. Pharmacogenomics J 15:354-62
Hirsch, Louis; Nazari, Hossein; Sreekumar, Parameswaran G et al. (2015) TGF-?2 secretion from RPE decreases with polarization and becomes apically oriented. Cytokine 71:394-6
Chuh, Kelly N; Pratt, Matthew R (2015) Chemical methods for the proteome-wide identification of posttranslationally modified proteins. Curr Opin Chem Biol 24:27-37
Zhang, Hongjun; Boddupally, Keerthi; Kandyba, Eve et al. (2014) Defining the localization and molecular characteristic of minor salivary gland label-retaining cells. Stem Cells 32:2267-77
Wu, Dai-Ying; Ou, Chen-Yin; Chodankar, Rajas et al. (2014) Distinct, genome-wide, gene-specific selectivity patterns of four glucocorticoid receptor coregulators. Nucl Recept Signal 12:e002
Su, Sheng-Fang; de Castro Abreu, André Luís; Chihara, Yoshitomo et al. (2014) A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence. Clin Cancer Res 20:1978-89
Tai, Kenneth P; Le, Valerie V; Selsted, Michael E et al. (2014) Hydrophobic determinants of ?-defensin bactericidal activity. Infect Immun 82:2195-202
Ng, Yuen-Keng; Lee, Jia-Ying; Supko, Kathryn M et al. (2014) Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res 24:207-18

Showing the most recent 10 out of 345 publications